Humanin
guinea pig
The Dose Guy’s verdictSep 1, 20264 sources
Humanin has one of the more interesting stories on the longevity shelf: a peptide your own mitochondria make, with animal data showing protection across stroke, heart attack, diabetes, and neurodegeneration. The problem is that nobody has given it to a person in a published study. Not once. The mechanism is real, the animal results are consistent, and the human evidence is limited to biomarker associations in blood draws. Until someone runs a human trial, humanin is a research bet, not a protocol.
What it is
Humanin is a 24-amino-acid peptide encoded by mitochondrial DNA, part of a family of mitochondrial-derived peptides that includes MOTS-c. Your cells make it naturally, and circulating levels decline with age. The mechanism runs through a cytokine receptor complex, CNTFR, WSX-1, and gp130, which connects it to cell survival and anti-inflammatory signaling. In lab and animal models, humanin and its more potent synthetic analogs like HNG and HNGF6A protect against oxidative stress, preserve insulin sensitivity, and reduce damage in stroke and heart models. The appeal is that it looks like part of the body’s own repair toolkit, fading exactly when aging accelerates.
What the research shows
Strong and consistent animal data across multiple disease models. Zero human administration studies:
Realistic protocols
No validated human dose exists. The community that experiments with humanin analogs typically injects subcutaneously in the low-milligram range, a few times per week, in short courses. That dosing is loosely extrapolated from the rodent pharmacology, where intraperitoneal HNG reached plasma but was undetectable in brain or heart tissue. Whether a subcutaneous dose in a person reaches the tissues that matter is unknown. If you run it, keep the course short. There is nothing specific to monitor because nobody has measured what to look for, and that is the problem. The glioblastoma data is a genuine caution: a peptide that promotes cell survival could promote the wrong kind of cell survival in the wrong context. If the mitochondrial-peptide angle interests you, MOTS-c has a more actionable profile on this shelf, though it too is early.
Side effects
No human side-effect data from administered humanin exists. What follows is inferred from the mechanism and animal work:
